317 completed. 317 Phase 2, 63 Phase 1, 38 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 317 | Completed 317 |
| Phase 1 | 63 | Completed 63 |
| Phase 3 | 38 | Completed 38 |
Follow Demyelinating Diseases: new trials by email Literature Review of Demyelinating Diseases trials Research Report on Demyelinating Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent RVP-001 - Central Nervous System (CNS) Lesions, Brain Metastases | Phase 2 | Completed | Reveal Pharmaceuticals Inc. | 18 | 2024-08-15 | 2025-12-26 |
| Propionic Acid in Multiple Sclerosis Propionic acid 1000 mg capsule, Placebo - Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Salzburger Landeskliniken | 101 | 2024-05-01 | 2026-09-15 |
| The CanISleepinMS Study: Effect of Cannabidiol (CBD) on Sleep Quality in Patients With Multiple Sclerosis Cannabidiol Oil - Sleep Quality, Multiple Sclerosis | Phase 2 | Completed | Wageningen University | 16 | 2024-03-26 | 2026-09-25 |
| Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis PIPE-307 Dose A, PIPE-307 Dose B, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Janssen Research & Development, LLC | 182 | 2023-11-06 | 2026-09-25 |
| A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) BIIB091, DRF, Placebo - Relapsing Forms of Multiple Sclerosis | Phase 2 | Completed | Biogen | 127 | 2023-07-25 | 2026-02-20 |
| Cognitive Reserve-building Activities in Multiple Sclerosis Cognitive Leisure Activities - Multiple Sclerosis | Phase 2 | Completed | Copenhagen University Hospital, Rigshospitalet | 60 | 2022-12-01 | 2025-02-18 |
| Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) Mitoxantrone Hydrochloride Liposome Injection - Neuromyelitis Optica Spectrum Disorder | Phase 2 | Completed | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 46 | 2022-11-28 | 2024-08-07 |
| A Teleheath tDCS Approach to Decrease Cannabis Use Transcranial Direct Current Stimulation (tDCS), Sham - Transcranial Direct Current Stimulation (tDCS), Mindfulness - Cannabis Use Disorder, Multiple Sclerosis | Phase 2 | Completed | NYU Langone Health | 52 | 2022-09-13 | 2025-06-24 |
| The Effect of Metformin As an Adjuvant Therapy on Immunological Parameters in Egyptian Patients with RRMS: a Pilot Study Metformin (Cidophage®), Usual Care - Multiple Sclerosis (MS) - Relapsing-remitting | Phase 2 | Completed | German University in Cairo | 30 | 2022-04-01 | 2025-02-06 |
| Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis Extracorporeal Photopheresis, MS standard of care - Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting | Phase 1 / Phase 2 | Completed | Abu Dhabi Stem Cells Center | 15 | 2022-03-26 | 2026-05-07 |
| HFS (High-Fiber Supplement) in MS (Multiple Sclerosis) NBT-NM108 - Multiple Sclerosis | Phase 1 / Phase 2 | Completed | Suhayl Dhib-Jalbut, MD | 7 | 2022-03-21 | 2024-12-17 |
| CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying Therapy Metformin and clemastine in combination, Placebo - Multiple Sclerosis | Phase 2 | Completed | Cambridge University Hospitals NHS Foundation Trust | 70 | 2022-03-08 | 2025-12-11 |
| Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders Belimumab - NMO Spectrum Disorder | Phase 1 / Phase 2 | Completed | Tianjin Medical University General Hospital | 14 | 2021-12-12 | 2024-10-16 |
| Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis HB-adMSCs, Placebo - Multiple Sclerosis | Phase 2 | Completed | Hope Biosciences Research Foundation | 24 | 2021-11-24 | 2025-09-26 |
| IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients plasmapheresis device, Intravenous immunoglobulin - Guillain-Barre Syndrome | Phase 2 / Phase 3 | Completed | Assiut University | 81 | 2021-09-01 | 2023-04-06 |
| High Frequency Impulse Therapy for Neuropathic Pain in NMOSD High Frequency Impulse Therapy, High Frequency Impulse Therapy - Sham - Neuromyelitis Optica | Phase 2 | Completed | Massachusetts General Hospital | 46 | 2021-06-07 | 2025-04-30 |
| Rehabilitative Protocols in Progressive Multiple Sclerosis Treated with Anti CD20 Monoclonal Antibodies Active Comparator #1, Placebo, Experimental - Multiple Sclerosis | Phase 2 | Completed | University of Pavia | 82 | 2021-06-01 | 2025-03-25 |
| Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis Methylprednisolone succinate, Normal saline - Multiple Sclerosis, Relapsing-Remitting, Magnetic Resonance Imaging | Phase 2 | Completed | Mazandaran University of Medical Sciences | 102 | 2021-05-22 | 2025-07-15 |
| Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) SAR445088 (IV), SAR445088 (SC) - Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Phase 2 | Completed | Bioverativ, a Sanofi company | 98 | 2021-04-28 | 2025-10-28 |
| An Open Label Study of the Effects of SHR1459 in NMOSDs Patients Drug - SHR1459 - Neuromyelitis Optica Spectrum Disorders | Phase 2 | Completed | Reistone Biopharma Company Limited | 10 | 2021-01-20 | 2023-03-23 |
Showing 20 of 317. Sign in to see all of them.
Multiple Sclerosis (214) · Multiple Sclerosis, Relapsing-Remitting (70) · Multiple Sclerosis, Chronic Progressive (36) · Neuromyelitis Optica (16) · Fatigue (12) · Leukodystrophy, Metachromatic (12) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (11) · Adrenoleukodystrophy (10) · Autoimmune Diseases (9) · Optic Neuritis (8) · Recurrence (8) · Muscle Spasticity (6) · Guillain-Barre Syndrome (5) · Leukodystrophy, Globoid Cell (4)
Nervous System Diseases (313) · Immune System Diseases (297) · Autoimmune Diseases of the Nervous System (292) · Autoimmune Diseases (285) · Demyelinating Autoimmune Diseases, CNS (277) · Pathological Conditions, Signs and Symptoms (93) · Pathologic Processes (67) · Disease Attributes (62) · Chronic Disease (53) · Multiple Sclerosis (49) · Central Nervous System Diseases (33) · Brain Diseases (29) · Signs and Symptoms (28) · Cranial Nerve Diseases (26)
Interferon beta-1a (16) · 4-Aminopyridine (11) · Rituximab (10) · Interferon beta-1b (8) · Glatiramer Acetate (7) · Natalizumab (7) · teriflunomide (7) · Thioctic Acid (6) · Fingolimod Hydrochloride (5) · Cyclophosphamide (4) · Daclizumab (4) · Dimethyl Fumarate (4) · Immunoglobulins, Intravenous (4) · Methylprednisolone (4) · Alemtuzumab (3)
Biogen (17) · National Institute of Neurological Disorders and Stroke (NINDS) (10) · Sanofi (8) · Oregon Health and Science University (7) · VA Office of Research and Development (7) · GlaxoSmithKline (6) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Copenhagen University Hospital, Rigshospitalet (5) · Isfahan University of Medical Sciences (5) · Novartis Pharmaceuticals (5) · Hadassah Medical Organization (4) · Johns Hopkins University (4) · Merck KGaA, Darmstadt, Germany (4) · Northwestern University (4) · Novartis (4)
United States (145) · Germany (53) · Canada (49) · United Kingdom (47) · Spain (43) · Russia (32) · Italy (31) · France (30) · Poland (29) · Czechia (26) · Denmark (19) · Netherlands (19) · Ukraine (19) · Hungary (17) · Bulgaria (16)
Paul Orchard, MD (4) · Emmanuelle Waubant, MD, PhD (3) · Fu-Dong Shi, MD,PhD (3) · Richard Burt, MD (3) · Bibiana Bielekova, M.D. (2) · Christoph Heesen, MD (2)
PMID 31072380, PMID 21586746, PMID 22622860, PMID 27411694, PMID 28129749, PMID 28607708, PMID 33023488, PMID 36163349, PMID 37715710, PMID 38729747, PMID 40267426, PMID 11386586, PMID 16567708, PMID 16971719, PMID 17058754, PMID 17502467, PMID 18272891, PMID 18398457, PMID 18507817, PMID 18572078, PMID 18645164, PMID 18671877, PMID 18703004, PMID 18946064, PMID 18952896, PMID 18970976, PMID 19317608, PMID 19364933, PMID 19442988, PMID 19491632, PMID 19833477, PMID 19847907, PMID 19847908, PMID 20003436, PMID 20163990, PMID 20483885, PMID 20621711, PMID 20659956, PMID 20803391, PMID 20937945, PMID 21135022, PMID 21397567, PMID 21570386, PMID 21697250, PMID 21738597, PMID 21803872, PMID 21960587, PMID 21978993, PMID 22047971, PMID 22065170
2009 (6), 2014 (4), 2005 (2), 2008 (2), 2018 (2), 2019 (2), P50AT000066 (2), 1IK2RX001180-01A2 (1), 2004 (1), 2015 (1), 2016 (1), 2017 (1), K23AT002155 (1), R01HD043323 (1), R01NS051591 (1)